FCF yield společnosti Starpharma
Jaká je hodnota metriky FCF yield společnosti Starpharma?
Hodnota metriky FCF yield společnosti Starpharma Holdings Limited je -3.25%
Jaká je definice metriky FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield společností v sektoru Health Care sektor na ASX ve srovnání se společností Starpharma
Čemu se věnuje společnost Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Firmy s metrikou fcf yield podobnou společnosti Starpharma
- Hodnota metriky FCF yield společnosti Deswell Industries je -3.27%
- Hodnota metriky FCF yield společnosti Peach Property AG je -3.27%
- Hodnota metriky FCF yield společnosti St. Augustine Gold and Copper je -3.26%
- Hodnota metriky FCF yield společnosti Quantify Technology je -3.26%
- Hodnota metriky FCF yield společnosti Bubblr Inc je -3.26%
- Hodnota metriky FCF yield společnosti Blackline Safety je -3.25%
- Hodnota metriky FCF yield společnosti Starpharma je -3.25%
- Hodnota metriky FCF yield společnosti Evergy je -3.24%
- Hodnota metriky FCF yield společnosti Arix Bioscience plc je -3.24%
- Hodnota metriky FCF yield společnosti Pennant International plc je -3.24%
- Hodnota metriky FCF yield společnosti Bioceres Crop Solutions Corp je -3.23%
- Hodnota metriky FCF yield společnosti Ceres Power Hldgs Ls ,10 je -3.23%
- Hodnota metriky FCF yield společnosti Shake Shack je -3.23%